r0.6c transmission blocking vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2021 (NCT04862416)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04862416 | Phase 1 | May 17, 2021 | Novavax, Radboud University, Statens Serum Institut |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 1 | 0 | 1 | 2021 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Statens Serum Institut | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1